After several years of robust expansion, the leading branded pharma companies will see growth slow to just 1.3% from now to 2015, independent market analyst company Datamonitor said in a new report. The primary culprit: expiring patents and an onslaught of generic competition.
Continue reading A Depressing Outlook for Big Pharma’s Next Few Years
A Depressing Outlook for Big Pharma’s Next Few Years originally appeared on DailyFinance on Mon, 24 Jan 2011 07:30:00.
Filed Under: Company News, Economy, Investing, Health Care, GlaxoSmithKline, Novartis